Table 3

Adjusted HRs of serious infection in patients with PsA versus RA treated with tumour necrosis factor inhibitor

NumberHR (95% CI)P value
Model A: adjusted for age and gender
 PsA vs RA26750.59 (0.41 to 0.85)0.004
Model B: adjusted for age, gender, DAS28-CRP, MHAQ
 PsA vs RA26750.58 (0.40 to 0.84)0.004
Model C: adjusted for age, gender, concomitant MTX, baseline prednisolone
 PsA vs RA26750.69 (0.47 to 1.00)0.049
Model C1: adjusted for age, gender, concomitant MTX
 PsA vs RA26750.59 (0.41 to 0.85)0.005
Model C2: adjusted for age, gender, baseline prednisolone any dose
 PsA vs RA26750.69 (0.48 to 1.00)0.048
Model C3: adjusted for age, gender, baseline prednisolone low dose
 PsA vs RA26750.60 (0.42 to 0.86)0.006
Model C4: adjusted for age, gender, baseline prednisolone intermediate dose
 PsA vs RA26750.64 (0.44 to 0.92)0.017
Model C5: adjusted for age, gender, baseline prednisolone high dose
 PsA vs RA26750.62 (0.43 to 0.90)0.011
Model D: adjusted for age, gender, COPD and/or asthma, diabetes
 PsA vs RA26750.58 (0.40 to 0.83)0.003
Model E: adjusted for all variables in models A–D
 PsA vs RA26750.65 (0.44 to 0.95)0.025
  • COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; DAS28, Disease Activity Score for 28 joints; MHAQ, Modified Health Assessment Questionnaire; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis.